Altimmune (NASDAQ:ALT) Shares Down 7%

Altimmune, Inc. (NASDAQ:ALT - Get Free Report)'s stock price traded down 7% during mid-day trading on Monday . The stock traded as low as $7.40 and last traded at $7.43. 1,628,236 shares were traded during trading, a decline of 71% from the average session volume of 5,598,546 shares. The stock had previously closed at $7.99.

Analyst Ratings Changes

ALT has been the topic of several research analyst reports. B. Riley reissued a "buy" rating and set a $20.00 target price on shares of Altimmune in a research report on Thursday, March 28th. The Goldman Sachs Group began coverage on shares of Altimmune in a report on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price objective on the stock. Finally, HC Wainwright lowered their target price on shares of Altimmune from $15.00 to $12.00 and set a "buy" rating for the company in a report on Monday, April 1st.

Altimmune Stock Performance

The business has a 50-day moving average of $9.72 and a 200-day moving average of $7.30. The stock has a market capitalization of $535.22 million, a price-to-earnings ratio of -4.58 and a beta of 0.05.

Hedge Funds Weigh In On Altimmune

Institutional investors have recently modified their holdings of the business. Osaic Holdings Inc. grew its stake in shares of Altimmune by 77.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,834 shares of the company's stock valued at $28,000 after purchasing an additional 3,416 shares during the last quarter. WealthPlan Investment Management LLC purchased a new position in Altimmune in the 3rd quarter valued at $31,000. FNY Investment Advisers LLC purchased a new position in Altimmune in the 4th quarter valued at $35,000. Keudell Morrison Wealth Management acquired a new position in Altimmune in the 3rd quarter valued at $36,000. Finally, Brave Asset Management Inc. purchased a new position in Altimmune during the 3rd quarter worth $39,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.